Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2297553
Max Phase: Preclinical
Molecular Formula: C26H32N2O4S
Molecular Weight: 468.62
Molecule Type: Small molecule
Associated Items:
ID: ALA2297553
Max Phase: Preclinical
Molecular Formula: C26H32N2O4S
Molecular Weight: 468.62
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCC[C@H](S)C(=O)NC1(C(=O)NC(Cc2ccc(-c3ccccc3)cc2)C(=O)O)CCCC1
Standard InChI: InChI=1S/C26H32N2O4S/c1-2-8-22(33)23(29)28-26(15-6-7-16-26)25(32)27-21(24(30)31)17-18-11-13-20(14-12-18)19-9-4-3-5-10-19/h3-5,9-14,21-22,33H,2,6-8,15-17H2,1H3,(H,27,32)(H,28,29)(H,30,31)/t21?,22-/m0/s1
Standard InChI Key: MJEAJLOGMRNZPB-KEKNWZKVSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 468.62 | Molecular Weight (Monoisotopic): 468.2083 | AlogP: 3.99 | #Rotatable Bonds: 10 |
Polar Surface Area: 95.50 | Molecular Species: ACID | HBA: 4 | HBD: 4 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 3.97 | CX Basic pKa: | CX LogP: 4.78 | CX LogD: 1.60 |
Aromatic Rings: 2 | Heavy Atoms: 33 | QED Weighted: 0.40 | Np Likeness Score: -0.26 |
1. Tanneeru K, Sahu I, Guruprasad L. (2013) Ligand-based drug design for human endothelin converting enzyme-1 inhibitors, 22 (9): [10.1007/s00044-012-0433-z] |
Source(1):